FDA Lays Out Requirements for ANDA Post-CRL Meetings

Generic Line
The FDA will agree to meet to discuss the ANDA deficiencies cited in a complete response letter to a sponsor only if the sponsor lists the questions it wants to raise and the people who will participate in the meeting and includes other items spelled out by the agency in draft guidance, the FDA said.

To View This Article:


Subscribe To Generic Line